The selection of this first target is a key step for the partnership between Medigene and WuXi Biologics, which aims to advance multiple TCR-TCEs over the next three years. The collaboration seeks to ...

Medigene announces KRAS G12V as first target for TCR-guided T cell engagers: Planegg, Germany Tuesday, December 10, 2024, 17:00 Hrs [IST] Medigene AG, an oncology platform company ...

PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting ...

The firms partnered earlier this year to leverage each other's technologies and develop multiple T-cell receptor-guided T-cell engagers.

lumc.nl Objective The presence of anti-citrullinated protein antibodies (ACPA) and IgM-rheumatoid factor (IgM-RF) years before the clinical diagnosis of rheumatoid arthritis (RA) suggests they are ...

生化试剂 KRAS Polyclonal Antibody,KRAS抗体由爱必信(上海)生物科技有限公司为您提供，如想了解更多关于抗体/抗原 KRAS Polyclonal Antibody,KRAS抗体的报价、规格、厂家等信息，欢迎来电或留言咨询。除供应KRAS Polyclonal Antibody,KRAS抗体外，爱必信(上海)生物科技有限公司还可 ...

kids.wustl.edu OBJECTIVE To evaluate muscle pathology and clinical characteristics in patients with a myopathy and serum antibodies to the Jo-1 antigen (histidyl t-RNA synthetase). BACKGROUND ...

Serum samples for anti-panitumumab antibody testing were collected from ... single-arm trial that estimated the effect of tumor KRAS status (wild-type or mutant) on efficacy endpoints in patients ...

PureTech Health (PRTC) presented data from the dose escalation phase of its ongoing Phase 1b trial evaluating LYT-200, an anti-galectin-9 ...

Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into ...

Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, today announced the appointment of Peter Olson, Ph.D. to the ...